Aduro Biotech to Present at Two Investor Conferences in May
April 25 2017 - 8:00AM
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T.
Isaacs, chairman, president and chief executive officer of Aduro,
will present at the following investor conferences in May 2017:
- 42nd Annual Deutsche Bank Health Care Conference in Boston, MA
on Wednesday, May 3, 2017 at 8:00 am Eastern Time
- Bank of America Merrill Lynch 2017 Heath Care Conference in Las
Vegas, NV on Thursday, May 18, 2017 at 10:00 am Pacific Time
To access the live webcasts and subsequent archived recordings
of these and other company presentations, please visit Aduro's
website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company
focused on the discovery, development and commercialization of
therapies that transform the treatment of challenging diseases.
Aduro's technology platforms, which are designed to harness the
body's natural immune system, are being investigated in cancer
indications and have the potential to expand into autoimmune and
infectious diseases. Aduro's LADD technology platform is based on
proprietary attenuated strains of Listeria that have been
engineered to express tumor-associated antigens to induce specific
and targeted immune responses. This platform is being developed as
a treatment for multiple indications, including mesothelioma,
ovarian, lung and prostate cancers. Additionally, a personalized
form of LADD, or pLADD, is being developed utilizing tumor
neoantigens that are specific to an individual patient’s tumor.
Aduro's STING Pathway Activator platform is designed to activate
the STING receptor in immune cells, resulting in a potent
tumor-specific immune response. ADU-S100 is the first STING Pathway
Activator compound to enter the clinic and is currently being
evaluated in a Phase 1 study in patients with cutaneously
accessible metastatic solid tumors or lymphomas. Aduro’s B-select
monoclonal antibody platform includes a number of immune modulating
assets in research and preclinical development. Aduro is
collaborating with leading global pharmaceutical companies to
expand its products and technology platforms. For more information,
please visit www.aduro.com.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Susan Lehner
510 809 2137
press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Sep 2023 to Sep 2024